Evidence map›Paper›PMID 42180050›Full record

ArticleFrontiers in oncology2026

Leveraging CT-based online adaptive radiotherapy for dose escalation in hypofractionated radiotherapy for locally advanced unresectable lung cancer.

Simran Alexandria Polce, Nour Nasser, Celina Chiodo, Janelle Brewer, Sarah Dooley, Ibrahim M Oraiqat, Jacqueline M Andreozzi, Vladimir Semenenko, Gage Redler, Stephen A Rosenberg

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simran Alexandria PolceDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Nour NasserDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Celina ChiodoDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Janelle BrewerDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Sarah DooleyDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Ibrahim M OraiqatDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Jacqueline M AndreozziDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Vladimir SemenenkoDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Gage RedlerDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Stephen A RosenbergDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard treatment for locally advanced (LA) lung cancer is surgery or concurrent chemoradiotherapy (CRT), but many patients are ineligible due to comorbidities. Sequential radiation (RT) and chemotherapy offer lower local control (LC) rates. Dose escalation and hypofractionation are emerging options for locally advanced (LA) NSCLC patients ineligible for surgery or chemoradiotherapy. However, toxicity rates remain unacceptable (G3-esophagitis up to 24%, G3-pneumonitis up to 12%). We have developed a novel approach that leverages CT-based online adaptive radiotherapy (oART) to deliver a simultaneously integrated boost while respecting OAR constraints. The oART workflow consists of image acquisition, patient modeling/contouring, plan generation/selection, verification image match (CBCT-to-CBCT), and treatment delivery. Targets were rigidly propagated and aligned daily; critical OARs were recontoured to account for inter-fraction variability and ensure OAR tolerances were not exceeded for daily treatment. Here, we outline our technical approach.

Indexed as

adaptive radiotherapydose escalationlocally advanced lung cancerNSCLCunresectable lung cancer

Identifiers

PMID42180050
PMCPMC13189974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.